MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Doxorubicin hydrochloride

CAS No. : 25316-40-9

MCE 站：Doxorubicin hydrochloride

产品活性：Doxorubicin (Hydroxydaunorubicin) hydrochloride是一种具有细胞毒性的蒽环类抗生素，是一种抗癌化疗试剂。Doxorubicin hydrochloride 是一种有效的人类 DNA topoisomerase I 和 topoisomerase II 抑制剂，IC₅₀ 分别为 0.8 μM 和 2.67 μM。Doxorubicin hydrochloride 可降低 AMPK 及其下游靶蛋白乙酰辅酶 A 羧化酶的磷酸化。还可诱导凋亡 (apoptosis) 和自噬。

研究领域：Antibody-drug Conjugate/ADC Related  |  Epigenetics  |  PI3K/Akt/mTOR  |  Autophagy  |  Apoptosis  |  Anti-infection  |  Cell Cycle/DNA Damage

作用靶点：ADC Cytotoxin  |  AMPK  |  Autophagy  |  Apoptosis  |  HIV  |  HBV  |  Mitophagy  |  Bacterial  |  Antibiotic  |  Topoisomerase

In Vitro: Doxorubicin hydrochloride (1-8 ?M; 24 and 48 hours) decreases the viability of MCF-10F, MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner.
Doxorubicin hydrochloride (1 μM; 3 and 24 hours) results in Hct-116 human colon carcinoma cells reduction in G0/G1 phase and accumulation in G2 phase.
Doxorubicin hydrochloride (1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells; 48 hours) induces apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression.

In Vivo: Treatment with Doxorubicin (2 mg/kg) or Zoledronic acid (100 μg/kg) alone does not statistically significantly decrease final tumor volume compared with saline. Mice treated with Doxorubicin plus Zoledronic acid have statistically significantly smaller final tumor volumes than those treated with Doxorubicin alone.

相关产品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Toxins for Antibody-Drug Conjugate Research Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Antioxidants Compound Library  |  Oxygen Sensing Compound Library  |  Antibacterial Compound Library  |  NMPA-Approved Drug Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  Rapamycin  |  3-Methyladenine  |  LY294002  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Paclitaxel  |  Cycloheximide  |  Y-27632 dihydrochloride  |  SB 203580  |  Chloroquine  |  Acetylcysteine  |  Angiotensin II human  |  Deferoxamine mesylate  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Dexamethasone  |  Bortezomib  |  Metformin hydrochloride  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Dorsomorphin  |  Gemcitabine  |  U0126-EtOH  |  Verteporfin  |  Doxycycline (hyclate)  |  Decitabine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。